Smokin not sure probably not too much. Its more about the third party validation and moving forward. That alone will cause a very nice price increase.
Upon a deal announcement it wouldn't be a surprise when the negative voices become overly positive pumping the SP ahead of itself it has happened before.
As a investor my concern isn't so much the share price but seeing a partnership to move the pipeline forward. In time the share price will reflect fair value .
For now we are a hostage to the wild west of the OTC where we have learned the waters are treacherous for emerging bio.
Call me gullible but its hard to believe the Irish subsidiary will not be a major piece of this puzzle.
Hoping we get that partner soon.